Fig. 1.

Study design of the MAD phase of the healthy volunteers phase 1 study. Study design of the MAD phase comprising healthy adult subjects randomized 3:1 to receive taldefgrobep alfa or placebo administered subcutaneously. Dosing for the MAD phase occurred only after safety and tolerability were reviewed from at least three SAD panels. MAD multiple ascending dose, Q1W once-weekly dosing, Q2W once every 2 weeks dosing, SAD single ascending dose